Multi-drug resistance capacity for Mycobacterium leprae demands the profound need for developing new multi-targeted anti-leprosy drugs. Mur ligases (MurC, MurD, MurE, and MurF) involved in biosynthesis of bacterial cell wall peptidoglycan are the best known and validated targets for antibacterial therapy. Transition-state analogs, such as phosphonates, phosphinates, and sulfonamides have good inhibitory activity toward any one or two of these Mur ligases. With an objective of designing a better inhibitor targeting all of these four Mur ligases, we developed phenylsulfonamido-3-morpholinopropan-2-yl dihydrogen phosphate derivatives as multi-targeted small molecule inhibitors for Mur ligases and evaluated using virtual screening studies. The results suggested the 1-(3-acetyl phenyl sulfonamide)-3-morpholino propan-2-yl dihydrogen phosphate as a novel multiple inhibitor for M. leprae MurC-MurF ligases.